← board
GNTA
distress 3/10 · well-funded / low risk$1.59-3%today-74% from 52w high
Revenue
pre-revenue
Liquidity
$48M
Runway
7.0 yrs
Shares 1y
0%
Price & events
+18.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.0%
1D
+10.4%
1W
-13.6%
1M
+126.5%
3M
+19.6%
6M
-57.9%
1Y
-63.9%
2Y
—
5Y
-85.5%
All
Overview
- Market Cap
- $37.26M
- Volume
- 85.07K
- 52 Week Range
- $0.58 – $6.20
- Total Shares
- 23.43M
- Float Shares
- 13.87M
- Short %
- 0.36%
- % Held by Insiders
- 42.47%
- % Held by Institutions
- 7.38%
- RVOL
- 0.40x
- Beta
- 0.75
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-10-02HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.